{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:30:12Z","timestamp":1778866212877,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microvascular Research"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/j.mvr.2011.01.001","type":"journal-article","created":{"date-parts":[[2011,1,13]],"date-time":"2011-01-13T04:15:04Z","timestamp":1294892104000},"page":"269-273","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Irbesartan inhibits advanced glycation end product (AGE)-induced up-regulation of vascular cell adhesion molecule-1 (VCAM-1) mRNA levels in glomerular endothelial cells"],"prefix":"10.1016","volume":"81","author":[{"given":"Takanori","family":"Matsui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayaka","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayoshi","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho-ichi","family":"Yamagishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mvr.2011.01.001_bb0005","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000075627","article-title":"Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy","volume":"24","author":"Bolton","year":"2004","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.mvr.2011.01.001_bb0010","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1056\/NEJM198805193182007","article-title":"Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications","volume":"318","author":"Brownlee","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mvr.2011.01.001_bb0015","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1365-2362.2010.02317.x","article-title":"Advanced glycation end-products and the kidney","volume":"40","author":"Busch","year":"2010","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.mvr.2011.01.001_bb0020","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/sj.ki.5000014","article-title":"Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice","volume":"69","author":"Chow","year":"2006","journal-title":"Kidney Int."},{"key":"10.1016\/j.mvr.2011.01.001_bb0025","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s11906-007-0078-3","article-title":"Intensified inhibition of renin\u2013angiotensin system: a way to improve renal protection?","volume":"9","author":"Cravedi","year":"2005","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.mvr.2011.01.001_bb0030","doi-asserted-by":"crossref","first-page":"11654","DOI":"10.1016\/S0021-9258(18)99007-1","article-title":"Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo","volume":"266","author":"Dyer","year":"1991","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mvr.2011.01.001_bb0035","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1111\/j.1523-1755.2004.66004.x","article-title":"AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction","volume":"66","author":"Fukami","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.mvr.2011.01.001_bb0040","doi-asserted-by":"crossref","first-page":"11649","DOI":"10.1016\/S0021-9258(18)99006-X","article-title":"Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors","volume":"266","author":"Grandhee","year":"1991","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mvr.2011.01.001_bb0045","doi-asserted-by":"crossref","first-page":"590","DOI":"10.5551\/jat.3624","article-title":"Blockade of renin\u2013angiotensin system attenuates advanced glycation end products-mediated signaling pathways","volume":"17","author":"Kamioka","year":"2010","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.mvr.2011.01.001_bb0050","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mvr.2011.01.001_bb0055","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1440-1681.2008.05078.x","article-title":"Benazepril, an angiotensin-converting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting advanced glycation end-product-mediated pathways","volume":"36","author":"Liu","year":"2009","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.mvr.2011.01.001_bb0060","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/j.1552-4604.1998.tb04422.x","article-title":"Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects","volume":"138","author":"Marino","year":"1998","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.mvr.2011.01.001_bb0065","doi-asserted-by":"crossref","first-page":"F1229","DOI":"10.1152\/ajprenal.00074.2009","article-title":"Mesangial cell-derived factors alter monocyte activation and function through inflammatory pathways: possible pathogenic role in diabetic nephropathy","volume":"297","author":"Min","year":"2009","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.mvr.2011.01.001_bb0070","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1159\/000098004","article-title":"Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration","volume":"26","author":"Navarro","year":"2006","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.mvr.2011.01.001_bb0075","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1161\/01.HYP.0000203826.15076.4b","article-title":"Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy","volume":"47","author":"Ogawa","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.mvr.2011.01.001_bb0080","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrneph.2010.58","article-title":"The RAAS in the pathogenesis and treatment of diabetic nephropathy","volume":"6","author":"Ruggenenti","year":"2010","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.mvr.2011.01.001_bb0085","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.2337\/diabetes.48.10.2066","article-title":"Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation","volume":"48","author":"Singh","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.mvr.2011.01.001_bb0090","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1159\/000226586","article-title":"A new perspective on therapeutic inhibition of advanced glycation in diabetic microvascular complications: common downstream endpoints achieved through disparate therapeutic approaches?","volume":"30","author":"Sourris","year":"2009","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.mvr.2011.01.001_bb0095","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/BF03402128","article-title":"Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients","volume":"5","author":"Takeuchi","year":"1999","journal-title":"Mol. Med."},{"key":"10.1016\/j.mvr.2011.01.001_bb0100","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.2337\/diab.45.3.S65","article-title":"Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors","volume":"Suppl 3","author":"Vlassara","year":"1996","journal-title":"Diabetes"},{"key":"10.1016\/j.mvr.2011.01.001_bb0105","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1038\/ki.2009.401","article-title":"Role of oxidants\/inflammation in declining renal function in chronic kidney disease and normal aging","volume":"Suppl. 114","author":"Vlassara","year":"2009","journal-title":"Kidney Int."},{"key":"10.1016\/j.mvr.2011.01.001_bb0110","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.lfs.2008.09.027","article-title":"Intervention with cilostazol attenuates renal inflammation in streptozotocin-induced diabetic rats","volume":"19","author":"Wang","year":"2008","journal-title":"Life Sci."},{"key":"10.1016\/j.mvr.2011.01.001_bb0115","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1097\/01.ASN.0000065100.17349.CA","article-title":"Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy","volume":"14","author":"Wendt","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.mvr.2011.01.001_bb0120","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.2174\/1381612054367300","article-title":"Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy","volume":"11","author":"Yamagishi","year":"2005","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.mvr.2011.01.001_bb0125","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4161\/oxim.3.2.11148","article-title":"Advanced glycation end products (AGEs), oxidative stress and diabetic nephropathy","volume":"3","author":"Yamagishi","year":"2010","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.mvr.2011.01.001_bb0130","doi-asserted-by":"crossref","first-page":"20213","DOI":"10.1074\/jbc.M602110200","article-title":"Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression","volume":"281","author":"Yamagishi","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mvr.2011.01.001_bb0135","doi-asserted-by":"crossref","first-page":"952","DOI":"10.2174\/138945007781386884","article-title":"Molecular mechanisms of diabetic nephropathy and its therapeutic intervention","volume":"8","author":"Yamagishi","year":"2007","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.mvr.2011.01.001_bb0140","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1172\/JCI11771","article-title":"Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice","volume":"108","author":"Yamamoto","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.mvr.2011.01.001_bb0145","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1007\/s00125-006-0437-7","article-title":"Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation","volume":"49","author":"Yoshida","year":"2006","journal-title":"Diabetologia"}],"container-title":["Microvascular Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026286211000057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026286211000057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T05:54:26Z","timestamp":1758434066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026286211000057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S0026286211000057"],"URL":"https:\/\/doi.org\/10.1016\/j.mvr.2011.01.001","relation":{},"ISSN":["0026-2862"],"issn-type":[{"value":"0026-2862","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Irbesartan inhibits advanced glycation end product (AGE)-induced up-regulation of vascular cell adhesion molecule-1 (VCAM-1) mRNA levels in glomerular endothelial cells","name":"articletitle","label":"Article Title"},{"value":"Microvascular Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mvr.2011.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}